These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 16702818)

  • 21. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.
    Willemze R; Suciu S; Meloni G; Labar B; Marie JP; Halkes CJ; Muus P; Mistrik M; Amadori S; Specchia G; Fabbiano F; Nobile F; Sborgia M; Camera A; Selleslag DL; Lefrère F; Magro D; Sica S; Cantore N; Beksac M; Berneman Z; Thomas X; Melillo L; Guimaraes JE; Leoni P; Luppi M; Mitra ME; Bron D; Fillet G; Marijt EW; Venditti A; Hagemeijer A; Mancini M; Jansen J; Cilloni D; Meert L; Fazi P; Vignetti M; Trisolini SM; Mandelli F; de Witte T
    J Clin Oncol; 2014 Jan; 32(3):219-28. PubMed ID: 24297940
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [A pharmacokinetic study of the value of oral cytarabine ocfosfate in the treatment of hematological malignancies].
    Ueda Y; Mori S; Ito T; Maesako Y; Konishi H; Yagiri Y
    Rinsho Ketsueki; 1998 May; 39(5):348-54. PubMed ID: 9637884
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low-dose cytarabine-induced hepatic and renal dysfunction in a patient with myelodysplastic syndrome.
    Tanaka M; Kanamori H; Yamaji S; Mishima A; Fujita H; Fujisawa S; Murata T; Koharazawa H; Matsuzaki M; Mohri H
    Anticancer Drugs; 1999 Mar; 10(3):289-91. PubMed ID: 10327034
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I study of a continuous infusion of high-dose ara-C in conjunction with a fixed dose of 2'-deoxycytidine (IND 28108) in patients with refractory leukemia: an interim report.
    Grant S; Baker M; Bhalla K
    Leukemia; 1993 Dec; 7(12):1933-8. PubMed ID: 8255091
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low-dose cytosine arabinoside (Ara-C) therapy in the myelodysplastic syndromes and acute myelogenous leukemia.
    Maiolo AT; Foa P; Cortellaro M; Lambertenghi-Deliliers G; Colantoni A; Cesana B; Castoldi GL; Cazzola M; Giordano M; Riccardi A
    Haematologica; 1987; 72(1):61-5. PubMed ID: 3108098
    [No Abstract]   [Full Text] [Related]  

  • 26. [Acute myeloblastic leukemias and myelodysplasias: treatment with low doses of aracytine].
    Pignon B; Blaise AM; Boilletot A; Herbrecht R; Rozenbaum A; Flesch M; Audhuy B; Barats JC
    Nouv Rev Fr Hematol (1978); 1986; 28(6):345-8. PubMed ID: 3470706
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Severe anterior uveitis as a complication of high-dose cytosine-arabinoside.
    Moberg J; Carlsson M; Holm C; Koranyi G
    Acta Ophthalmol; 2009 Nov; 87(8):922-3. PubMed ID: 19799589
    [No Abstract]   [Full Text] [Related]  

  • 28. Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.
    Giles FJ; Faderl S; Thomas DA; Cortes JE; Garcia-Manero G; Douer D; Levine AM; Koller CA; Jeha SS; O'Brien SM; Estey EH; Kantarjian HM
    J Clin Oncol; 2003 Mar; 21(6):1050-6. PubMed ID: 12637470
    [TBL] [Abstract][Full Text] [Related]  

  • 29. AraU accumulation in patients with renal insufficiency as a potential mechanism for cytarabine neurotoxicity.
    Lindner LH; Ostermann H; Hiddemann W; Kiani A; Würfel M; Illmer T; Karsch C; Platzbecker U; Ehninger G; Schleyer E
    Int J Hematol; 2008 Nov; 88(4):381-386. PubMed ID: 18836794
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The pharmacokinetics of cytarabine in dogs when administered via subcutaneous and continuous intravenous infusion routes.
    Crook KI; Early PJ; Messenger KM; Muñana KR; Gallagher R; Papich MG
    J Vet Pharmacol Ther; 2013 Aug; 36(4):408-11. PubMed ID: 22943060
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [A phase II study with high-dose cytarabine (NS-075) in adult patients with relapsed and refractory acute leukemia].
    Miyawaki S; Mizoguchi H; Tomonaga M; Kanamaru A; Tsukagoshi S; Nakamura T; Ohashi Y; Yoshida S; Ohno R
    Gan To Kagaku Ryoho; 1998 Dec; 25(14):2229-42. PubMed ID: 9881080
    [TBL] [Abstract][Full Text] [Related]  

  • 32. "Flushing out" cytosine arabinoside from CSF to reverse neurotoxicity.
    Bleyer A
    J Pediatr Hematol Oncol; 2007 Apr; 29(4):274. PubMed ID: 17414574
    [No Abstract]   [Full Text] [Related]  

  • 33. [Bases for intravenous administration of cytosine arabinoside in the treatment of adult acute myeloid leukemia].
    Thomas X; Archimbaud E
    Bull Cancer; 1995 Nov; 82(11):911-22. PubMed ID: 8535017
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Treatment of myelodysplastic syndrome using continual subcutaneous infusion of low doses of cytosine arabinoside].
    Vozobulová V; Koza V; Cepelák V; Neuwirtová R; Masek Z
    Vnitr Lek; 1990 May; 36(5):483-8. PubMed ID: 2375080
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Very-low-dose cytarabine for myelodysplastic syndromes and acute myeloid leukaemia in the elderly.
    Worsley A; Mufti GJ; Copplestone JA; Oscier DG; Hamblin TJ
    Lancet; 1986 Apr; 1(8487):966. PubMed ID: 2871254
    [No Abstract]   [Full Text] [Related]  

  • 36. [Successful treatment of acute non-lymphoblastic leukemia from myelodysplastic syndrome by combination of human macrophage colony-stimulating factor (M-CSF) and low dose cytosine arabinoside: M-CSF-induced proliferation and tyrosine phosphorylation in leukemic blasts].
    Hagiwara S; Yuo A; Nagai M; Takezako N; Soda Y; Miwa A; Togawa A; Takaku F
    Rinsho Ketsueki; 1996 Nov; 37(11):1259-64. PubMed ID: 8960658
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Low dose cytosine arabinoside in the treatment of acute non-lymphoblastic leukemia.
    Insiripong S; Thaisamakr S
    J Med Assoc Thai; 1996 Sep; 79(9):568-71. PubMed ID: 8996985
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low-dose cytarabine plus aclarubicin for patients with previously untreated acute myeloid leukemia or high-risk myelodysplastic syndrome ineligible for standard-dose cytarabine plus anthracycline.
    Fukushima T; Kawabata H; Sawaki T; Satoh T; Nakamura T; Iwao H; Nakajima A; Sakai T; Miki M; Fujita Y; Tanaka M; Kawanami T; Masaki Y; Okazaki T; Umehara H
    Anticancer Res; 2012 Apr; 32(4):1347-53. PubMed ID: 22493369
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combination of decitabine, idarubicin, cytarabine, and G-CSF (DIAG) regimen for the treatment of high-risk myelodysplastic syndrome and acute myeloid leukemia.
    Zhang X; Guo X
    Ann Hematol; 2019 Sep; 98(9):2223-2225. PubMed ID: 30980106
    [No Abstract]   [Full Text] [Related]  

  • 40. Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group.
    Avramis VI; Wiersma S; Krailo MD; Ramilo-Torno LV; Sharpe A; Liu-Mares W; Kowck R; Reaman GH; Sato JK
    Clin Cancer Res; 1998 Jan; 4(1):45-52. PubMed ID: 9516951
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.